Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Entrada Therapeutics to similar companies based on the strength of its institutional ownership, profitability, dividends, analyst recommendations, valuation, earnings and risk.
Profitability
This table compares Entrada Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entrada Therapeutics | -4,057.98% | -64.00% | -50.49% |
| Entrada Therapeutics Competitors | -12,519.20% | -215.47% | -31.42% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Entrada Therapeutics and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entrada Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Entrada Therapeutics Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
Entrada Therapeutics presently has a consensus price target of $16.75, suggesting a potential upside of 285.06%. As a group, “Biotechnology” companies have a potential upside of 114.65%. Given Entrada Therapeutics’ higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than its peers.
Volatility & Risk
Entrada Therapeutics has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, Entrada Therapeutics’ peers have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.
Insider & Institutional Ownership
86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Entrada Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Entrada Therapeutics | $3.98 million | -$143.75 million | -1.13 |
| Entrada Therapeutics Competitors | $746.10 million | $10.34 million | -17.98 |
Entrada Therapeutics’ peers have higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
Entrada Therapeutics peers beat Entrada Therapeutics on 7 of the 13 factors compared.
Entrada Therapeutics Company Profile
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
